Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Inclusion Criteria: * History or active diagnosis of cancer (solid or hematologic) or precursor of cancer (monoclonal gammopathy of undetermined significance \[MGUS\]), monoclonal B lymphocytosis (MBL), aplastic anemia or myelodysplastic syndrome) that is associated with immune suppression * Hospitalization for confirmed polymerase chain reaction (PCR) positive COVID-19 infection * Patients with evidence of pulmonary involvement who meet any of the followings; presence of infiltrates on chest X-ray or computed tomography (CT) scan or need for supplemental oxygen \< 8 L nasal cannula or pulse oximetry \< 94% on room air * Creatinine clearance \>= 25 ml/min by Cockcroft-Gault equation * Total bilirubin =\< 1.5 x upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN * Absolute neutrophil count (ANC) \>= 1000/mm\^3 independent of growth factor support * Platelets \>= 50,000/mm\^3 * Ability to swallow capsules * Ability to provide informed consent indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study * Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating…